Arley VDA, Castro AE

Idioma: Español
Referencias bibliográficas: 32
Paginas: 1-7
Archivo PDF: 403.77 Kb.

RESUMEN

La enfermedad renal crónica es una entidad prevalente y de alta mortalidad, la cual se encuentra subdiagnosticada por problemas de registro a nivel mundial, dentro de sus complicaciones se destaca el trastorno mineral óseo el cual favorece las calcificaciones vasculares y el riesgo cardiovascular en esta población. El uso de los calcio miméticos genera un control adecuado del hiperparatiroidismo secundario en los pacientes nefrópatas en diálisis en especial cuando se realiza un manejo conjunto con otros fármacos destinados al control del trastorno mineral óseo; y además, logra una reducción del riesgo cardiovascular.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Eknoyan, G. et al. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements (2013). VOL 3 | ISSUE 1 | JANUARY (1) 2013.

2. Webster, A. et al. Chronic kidney disease. Lancet 2017; 389: 1238–52. http://dx.doi.org/10.1016/ S0140-6736(16)32064-5

3. Romagnani, P. Et Al. Chronic Kidney Disease. Nature Reviews | Disease Primers Volume 3 | Article Number 17088 | 3. Doi:10.1038/Nrdp.2017.88

4. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. (2016) Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE 11(7): e0158765. doi:10.1371/journal.pone.0158765

5. Ministerio de Salud, Mortalidad Por Insuficiencia Renal Crónica: Costa Rica. (2016). Informe Estadístico.

6. Rivera, A. et Méndez, E. Mortalidad y egresos hospitalarios por enfermedad renal crónica compatibles con enfermedad crónica de causas no tradicionales, Costa Rica. Acta méd costarric Vol 58 (1), enero-marzo 2016.

7. Torregrosa, J. et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.- MM). Nefrologia 2011;31(Suppl.1):3-32. doi:10.3265/ Nefrologia.pre2011.Jan.10816

8. Eknoyan, G. et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease– Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements (2017) 7, 1–59. http://dx. doi.org/10.1016/j.kisu.2017.04.001.

9. García, P. Et al. Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis. Med Princ Pract 2011;20:203–212 DOI: 10.1159/000323434.

10. Rodríguez, M. et al. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review. Seminars in Dialysis— 2015. DOI: 10.1111/sdi.12357

11. Querido, S. et al. Cinacalcet in peritoneal dialysis patients: one-center experience. J Bras Nefrol 2017;39(1):42-45. DOI: 10.5935/0101-2800.20170007

12. Wheeler, D. et al. Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Am Heart Assoc. 2014;3:e001363 doi: 10.1161/JAHA.114.001363.

13. Parfrey, P. et al. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 10: ccc–ccc, 2015. doi: 10.2215/CJN.07730814.

14. Moe, S. et al. Cinacalcet, Fibroblast Growth Factor- 23, and Cardiovascular Disease in Hemodialysis. The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132:27-39. DOI: 10.1161/CIRCULATIONAHA. 114.013876.

15. Floege, J. et al. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol 10: 800–807, 2015. doi:10.2215/CJN.10221014.

16. Friedl C, et al, Mortality in dialysis patients with cinacalcet use: A large observational registry study, Eur J Intern Med (2017), http://dx.doi.org/10.1016/j. ejim.2017.05.002

17. Moe, S. Et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol 26: ccc–ccc, 2014. doi: 10.1681/ASN.2014040414

18. Zawierucha, J. Et al. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients. POLISH ARCHIVES OF INTERNAL MEDICINE 2017; 127 (12). doi:10.20 452/pamw.4124

19. Bover, J. Et al. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Clin J Am Soc Nephrol: ccc–ccc, 2015. doi: 10.2215/CJN.01760215.

20. Brunelli, S. Et al. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. pharmacoepidemiology and drug safety 2015; 24: 1058–1067. DOI: 10.1002/pds.3845

21. Cozzolino, M. Et al. Treatments for secondary hyperparathyroidism in hemodialysis. Pol Arch Intern Med. 2017; 127 (12): 807-809 doi:10.20452/ pamw.4170

22. Akizawa, T. Et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific RepoRts | 6:19612 | DOI: 10.1038/srep19612

23. Jeong, S. Et al. Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Design, Development and Therapy 2016:10 2211–2225. http://dx.doi.org/10.2147/ DDDT.S103370

24. Moe, S. Et al. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clin J Am Soc Nephrol 12: ccc–ccc, 2017. doi: https://doi.org/10.2215/CJN.11141016

25. Rroji, M. Et al. Calcimimetics versus parathyroidectomy: What is preferable?. International Urology and Nephrology https://doi.org/10.1007/s11255- 018-1838-5.

26. Van der Plas, W. Et al. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transplant (2017) 32: 1902–1908 doi: 10.1093/ndt/gfx044.

27. Lin Chen, Kongbo Wang, Shanlan Yu, Liping Lai, Xiaoping Zhang, Jingjing Yuan & Weifeng Duan (2016): Long–term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta- analysis, Renal Failure, DOI: 10.1080/0886022X.2016.1184924

28. Sekercioglu, N. Et al. Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis. Sekercioglu et al. Systematic Reviews (2016) 5:2 DOI 10.1186/ s13643-015-0177-1

29. Pérez-Ricart A, Galicia-Basart M, Alcalde- Rodrigo M, Segarra-Medrano A, Suñé-Negre J-M, Montoro- Ronsano J-B (2016) Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. PLoS ONE 11(9): e0161527. doi:10.1371/ journal. pone.0161527

30. Yuan, F. Et al. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Blood Purif 2018;45:73–78. DOI: 10.1159/000484435.

31. Wetmore, J. Et al. A Randomized Trial of Cinacalcet versus Vitamin D. Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10: ccc–ccc, 2015. doi: 10.2215/CJN.07050714

32. Nigar Sekercioglu, Jason W. Busse, M. Fatih Sekercioglu, Arnav Agarwal, Shaun Shaikh, Luciane Cruz Lopes, Reem A. Mustafa, Gordon H. Guyatt & Lehana Thabane (2016): Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis, Renal Failure, DOI: 10.3109/0886022X.2016.1172468